COVID-19’s impact on digital health

The global pandemic has caused businesses in all sectors to rethink their operations, priorities, and roadmap. But what about biopharma? How have they adapted to COVID-related challenges—and how lasting will the effects be?

We sent our top five questions on the topic to leaders in biopharma, and we’ve compiled the results in an illuminating infographic.

Executives from Johnson & Johnson, Sanofi, Merck, and other leading biopharma companies

shared whether the global pandemic has caused them to focus more on their digital health efforts and how they’re handling clinical trials in the era of social distancing. We dug into which areas of digital health are their main priorities. Plus, we got their thoughts on the current state of their organizations’ digital maturity and where they see it going in the next three to five years.

You don’t want to miss these powerful insights. Take a look at the full infographic here.

Digital health is the way forward

What’s clear is that the COVID-19 global pandemic has been a major factor in the acceleration of digital health initiatives among leading biopharma companies. During pandemic times and beyond, the companies who prioritize digital and stand up solutions quickly will be those who lead the pack.

As the leading global regulated digital health platform for biopharma, BrightInsight helps organizations build, scale, and maintain their digital health innovations in a compliant manner. We accelerate time to market for digital health solutions and do it while minimizing biopharma customer risk. Reach out today to learn more.

Back to Blog